Celsion takes a nosedive as board recommends trial halt; Three biotech IPOs set terms above $90M
→ Celsion’s stock has fallen down a drainpipe after the biotech disclosed this morning that their independent review board recommended …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
